US biopharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) announced on Tuesday the publication of an original research article titled 'Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis' in the New England Journal of Medicine (NEJM) Evidence.
The findings of this pivotal phase III study are included in the Biologics License Application (BLA) for imsidolimab for the treatment of Generalised Pustular Psoriasis (GPP), submitted to the US Food and Drug Administration (FDA) with a target action date of 12 December 2026.
Imsidolimab is a fully humanised IgG4 monoclonal antibody that inhibits IL-36 receptor signalling and is being developed for GPP, a rare orphan indication. Regulatory and patent exclusivity for imsidolimab is expected to extend into the late 2030s.
Vanda holds an exclusive global licence for the development and commercialisation of imsidolimab from AnaptysBio (Nasdaq:ANAB).
Xbrane resubmits FDA application for ranibizumab biosimilar after facility remediation
European Commission clears first pertuzumab biosimilar in Europe
Vanda Pharmaceuticals reports publication of imsidolimab phase III findings in NEJM Evidence
C-Ray Therapeutics' Copper-64 (Cu-64) Type II DMF gains FDA acceptance
GSK hepatitis B therapy bepirovirsen gains FDA priority review and breakthrough designation
Xcovery and EVERSANA partner for US commmercialisation of lung cancer drug Ensacove
Novartis secures European approval for remibrutinib in chronic spontaneous urticaria
Evofem signs exclusive deal to expand SOLOSEC distribution in sub-Saharan Africa
GSK secures US and EU fast-track designations for efimosfermin in MASH
AstraZeneca secures US approval for Saphnelo self-administration in lupus treatment
Abbott presents late-breaking clinical data on treating heart rhythm disorders